Strimvelis market forecast points to growth through 2026

The Strimvelis gene therapy market is expected to expand through 2026 as rare disease diagnoses rise, healthcare spending increases and personalized medicine gains ground. North America held the largest share in 2025, while Asia-Pacific is projected to grow fastest over the forecast period.

Why it matters: - Strimvelis is a gene therapy for ADA-SCID, a rare and life-threatening immune disorder. - Market growth matters because the therapy depends on advanced treatment infrastructure, rare disease awareness and access to specialized care. - Wider adoption of gene therapies could expand treatment options for patients with rare genetic diseases.

What happened: - The Business Research Company released a market analysis on Strimvelis on November 12, 2026. - The report says the Strimvelis market is positioned for notable growth through 2026. - North America held the largest share of the Strimvelis market in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period.

The details: - Strimvelis treats adenosine deaminase deficiency-severe combined immunodeficiency, or ADA-SCID. - The therapy collects a patient’s own stem cells, modifies them to correct the defective ADA gene and reinfuses the corrected cells. - That process is designed to restore immune function and may offer a long-lasting cure for the condition. - The market’s past growth was driven by stem cell modification breakthroughs and early ada-scid gene therapy trials. - Supportive orphan-drug regulations, greater awareness of rare immunodeficiency diseases and centralized treatment centers also helped the market expand. - Future growth is expected to come from commercialization of gene therapies, higher investment in rare disease research and more personalized medicine use. - Advances in vector design and broader global access to advanced gene therapies are also expected to support growth. - Key trends highlighted in the report include ex vivo gene therapies, personalized genetic treatments, autologous stem cell platforms and rare-disease gene therapy programs. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market-hotspots infographics, and updated technology and trend analysis. - The report offers a free sample and a full report through the company’s website: Free sample report and full market report.

Between the lines: - The report frames rare-disease gene therapy as a market driven by both clinical need and reimbursement-ready healthcare systems. - Rising healthcare spending is helping fund research, development and patient access to advanced therapies. - Personalized medicine remains a major tailwind because Strimvelis is built around a patient-specific cell modification process. - The regional split suggests mature markets are currently capturing most demand, while emerging healthcare systems are building toward faster growth. - The report cites external indicators, including NHS data showing about 17,000 people in England live with sickle cell disease and about 250 new cases are identified each year. - The report also cites American Medical Association data showing U.S. healthcare spending rose 7.5% in 2023 to $4.9 trillion, or $14,570 per person. - It further cites Personalized Medicine Coalition data showing the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

What's next: - The market’s next phase will depend on broader gene-therapy commercialization and more investment in rare-disease pipelines. - Wider access to advanced treatment centers could support adoption beyond current leading regions. - Further growth will likely track advances in precision diagnostics, vector design and autologous cell therapy platforms.

The bottom line: - Strimvelis is moving from niche therapy to a market with broader growth potential, powered by rare-disease demand, personalized medicine and expanding gene-therapy infrastructure.